Except for the G2/M phase, a similar pattern of cyclin and CDKI expression was observed in the controls and MM patients.
5 35 62 Table 5: Comparison of Cyclins and CDKIs Between Phases in the Patient Groups Group Cyclin/CDKI G0/G1-S G0/G1-G2/M S-G2/M A P< 0.
CDKI p16 expression in the control group was significantly higher during the GO/G1 phase than during the S phase (P < 0.
CDKI p16 expression the in MM group was similar to that in the control group.
Distribution of cyclins and CDKIs during the G2/M phase was similar in the MM and control groups, whereas cyclin expression was similar during all 3 phases in the MM and CML groups.
In normal and hematologically malignant cells partial illumination of the cell cycle--and thus the etiopathology of malignancy--can only be determined via comparison of the quantified changes in the cyclical phases of cyclins and CDKIs in healthy and malignant proliferated cells.
Comparison of the cell cycle-regulating elements cyclin A, B, D, and E, and CDKIs p16 and p21 in the control group showed that cyclin D was expressed most frequently during the GO/G1 phase; the other cyclins were present in 33% of the cells, and the cyclin E level was very low.
Expression of cyclins A, B, D, and E, and CDKIs p21 and p16 during the GO/G1 and S phases were similar in the CML patients and controls (P > 0.
The present study used flow cytometry to analyze the expression of cyclins A, B, D, and E, and CDKIs p21 and p16 in patients with CML and MM, and controls.